3SBioSTU:83B -1.38%90 ROE % is 65.57% as of Dec. 2025, which is 371% above its 10-year median of 13.91. GuruFocus rates STU:83B with a GF Score™ of 90/100 and a GF Value™ of €1.49 (Modestly Overvalued). The stock has 1 warning sign investors should review. Among 1,252 Biotechnology companies, 3SBio ranks better than 96.09% on this metric.
ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. 3SBio's annualized net income for the quarter that ended in Dec. 2025 was €1,728 Mil. 3SBio's average Total Stockholders Equity over the quarter that ended in Dec. 2025 was €2,635 Mil. Therefore, 3SBio's annualized ROE % for the quarter that ended in Dec. 2025 was 65.57%.
The historical rank and industry rank for 3SBio's ROE % or its related term are showing as below:
STU:83B'
s ROE % Range Over the Past 10 Years
Min: 8.47 Med: 13.91 Max: 43.59
Current: 43.59
During the past 12 years, 3SBio's highest ROE % was 43.59%. The lowest was 8.47%. And the median was 13.91%.
STU:83B's ROE % is ranked better than 96.09% of 1252
companies
in the Biotechnology industry
Industry Median: -38.145
vs STU:83B: 43.59
3SBio (STU:83B) ROE % Explanation
ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.
The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:
Note:
The net income data used here is two times the semi-annual (Dec. 2025) net income data. The Revenue data used here is two times the semi-annual (Dec. 2025) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Net Income is used.
Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.
3SBio ROE % Related Terms
3SBio ROE % Historical Data
* Premium members only.
The historical data trend for 3SBio's ROE % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, 3SBio's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
3SBio ROE % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, 3SBio's ROE % distribution charts can be found below:
* The bar in red indicates where 3SBio's ROE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is two times the semi-annual (Dec. 2025) net income data.
ROE % is displayed in the 30-year financial page.
3SBio (STU:83B) has a ROE % of 65.57% as of Dec. 2025. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on 3SBio and its competitors. This is 371% above median its historical median of 13.91. Over the past decade, 3SBio's ROE % has ranged from 8.47 to 43.59. According to the industry distribution chart, 3SBio ranks #49 out of 1252 companies in the Biotechnology industry, placing it in the top 3.9%.
Is 3SBio's ROE % too high?
3SBio's current ROE % of 65.57% is 371% above median its 10-year median of 13.91. Over the past 10 years, this metric has ranged from a low of 8.47 to a high of 43.59. Based on the distribution chart, 3SBio ranks #49 out of 1252 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, 3SBio has a GF Score™ of 90/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does 3SBio's ROE % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, 3SBio ranks #49 out of 1252 companies for ROE %. This places 3SBio in the top 4% of its industry — outperforming the majority of peers. Historically, 3SBio's own ROE % has ranged from 8.47 to 43.59 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % for a Biotechnology company?
A good ROE % depends on the Biotechnology industry context. However, ROE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % mean?
A high ROE % can signal that a stock is expensive relative to its fundamentals. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on 3SBio and its competitors. 3SBio's current ROE % is 65.57%, which is 371% above median its own 10-year median of 13.91. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is 3SBio stock overvalued right now?
Based on GuruFocus' analysis, 3SBio (STU:83B) is currently considered Modestly Overvalued. The stock's GF Value™ is €1.49, compared to a current price of €1.70 — trading 14.4% above its estimated fair value. The current ROE % is 65.57%, which is 371% above median its 10-year median of 13.91. 3SBio's overall GF Score™ is 90/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % calculated?
ROE % is calculated from a company's financial statements. For 3SBio (STU:83B), the current ROE % is 65.57% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is 3SBio (STU:83B) Overvalued in 2026?
Based on GuruFocus' analysis, 3SBio stock appears to be overvalued.
The current stock price of €1.70 is trading 14.4% above its estimated GF Value™ of €1.49.
GuruFocus considers 3SBio to be Modestly Overvalued.
Key valuation signals for STU:83B:
ROE %: 65.57% (371% above median its 10-year median of 13.91)
GF Value™: €1.49 vs. price of €1.70 (14.4% above fair value)
No single metric tells the full story. See the STU:83B stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
3SBio Inc is an investment holding company. It is a primary biotechnology company. The company is principally engaged in the development, production, marketing and sale of biopharmaceutical products in the People's Republic of China. The group has only one operating segment. It has presence in Chinese mainland, USA, Other countries/regions. The majority of revenue comes from USA. The core commercialized products of the group include several bio-pharmaceutical drugs, namely, TPIAO, recombinant human erythropoietin (rhEPO) products EPIAO and SEPO, Yisaipu and Cipterbin, and a small molecule drug, Mandi series of minoxidil drugs.
90GF Score
Get the complete analysis for STU:83B
ROE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:83B has been successfully added to your 
